Literature DB >> 15969672

The DR4-DQ8 haplotype and a specific T cell receptor Vbeta T cell subset are associated with absence of allergy to Can f 1.

T Kinnunen1, A Taivainen, J Partanen, A Immonen, S Saarelainen, M Rytkönen-Nissinen, J Rautiainen, T Virtanen.   

Abstract

BACKGROUND: The significance of specific T cell receptor (TCR) Vbeta subtypes and human leucocyte antigen (HLA) class II alleles for the development of allergy to lipocalin allergens such as the major dog allergen Can f 1 is not clear at present.
OBJECTIVE: To characterize the TCR Vbeta usage in the Can f 1-specific T cell lines and the HLA class II genotypes of Can f 1-allergic and non-allergic subjects.
METHODS: T cell lines were induced with recombinant Can f 1 from the peripheral blood mononuclear cells of 12 non-atopic dog owners and 26 dog-allergic patients. Thirteen of the dog-allergic subjects were sensitized to Can f 1. Expression of the TCR Vbeta subtypes on CD4(+) T cells in the T cell lines was measured by flow cytometry. The subjects were HLA genotyped for DRB1, DQB1 and DPB1 loci.
RESULTS: Can f 1-specific T cell lines were obtained from 18 subjects, with either positive (n=8) or negative (n=10) skin prick tests (SPTs) to recombinant Can f 1. The frequency of TCR Vbeta5.1(+) T cells was significantly higher in the T cell lines of subjects with negative SPTs to the allergen. Moreover, DR4-DQ8 haplotype was over-represented among these subjects.
CONCLUSION: The DR4-DQ8 haplotype and the TCR Vbeta5.1(+) CD4(+) T cells may be protective against allergy to Can f 1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969672     DOI: 10.1111/j.1365-2222.2005.02247.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  8 in total

1.  Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy.

Authors:  Anu K Immonen; Antti H Taivainen; Ale T O Närvänen; Tuure T Kinnunen; Soili A Saarelainen; Marja A Rytkönen-Nissinen; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

2.  Differential CD4+ T-cell responses of allergic and non-allergic subjects to the immunodominant epitope region of the horse major allergen Equ c 1.

Authors:  Anssi Kailaanmäki; Tuure Kinnunen; William W Kwok; Marja Rytkönen-Nissinen; Jukka Randell; Tuomas Virtanen
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

3.  Reply to the letter to the editor concerning the review Immunotherapy for pet allergies.

Authors:  Tuomas Virtanen
Journal:  Hum Vaccin Immunother       Date:  2018-04-11       Impact factor: 3.452

4.  Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues.

Authors:  Soili A Saarelainen; Tuure T Kinnunen; Cécile Buhot; Ale T O Närvänen; Anu K Kauppinen; Marja A Rytkönen-Nissinen; Bernard Maillere; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-10-16       Impact factor: 7.397

Review 5.  Inhalant Mammal-Derived Lipocalin Allergens and the Innate Immunity.

Authors:  Tuomas Virtanen
Journal:  Front Allergy       Date:  2022-01-27

6.  Human CD4+ T cell responses to the dog major allergen Can f 1 and its human homologue tear lipocalin resemble each other.

Authors:  Aino L K Liukko; Tuure T Kinnunen; Marja A Rytkönen-Nissinen; Anssi H T Kailaanmäki; Jukka T Randell; Bernard Maillère; Tuomas I Virtanen
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240

Review 7.  Structural similarities of human and mammalian lipocalins, and their function in innate immunity and allergy.

Authors:  E Jensen-Jarolim; L F Pacios; R Bianchini; G Hofstetter; F Roth-Walter
Journal:  Allergy       Date:  2015-11-23       Impact factor: 13.146

8.  Commentary: Allergen and Epitope Targets of Mouse-Specific T Cell Responses in Allergy and Asthma.

Authors:  Tuomas Virtanen; Marja Rytkönen-Nissinen
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.